Peripheral T-cell Lymphoma Clinical Trial
— FIL_GEMROOfficial title:
Phase IIa Study on the Role of Gemcitabine Plus Romidepsin (GEMRO Regimen) in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Patients.
NCT number | NCT01822886 |
Other study ID # | FIL_GEMRO |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | January 2013 |
Est. completion date | July 2018 |
Verified date | August 2018 |
Source | Fondazione Italiana Linfomi ONLUS |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Pilot clinical trial - Phase 2a, multicenter, single arm, open label trial - to evaluate efficacy and safety of concomitant combination treatment with Gemcitabine and Romidepsin (GEMRO) regimen as salvage treatment in relapsed/refractory PTCL (peripheral T-cell lymphoma) in a selected population of patients.
Status | Completed |
Enrollment | 20 |
Est. completion date | July 2018 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with histological diagnosis of PTCL according to the WHO (World Health Organization) classification - Age = 18 years - Relapsed (=1) or refractory to conventional chemotherapy/radiotherapy - Stage I-IV according to the Ann Arbor staging System - ECOG (Eastern Cooperative Oncology Group) Performance status =2 - Normal renal and hepatic functions - Laboratory test results as follows: - Serum creatinine = 2.0 mg/dL - Total bilirubin = 1.5 mg/dL - AST (SGOT) and ALT (SGPT) £2 x ULN or £5 x ULN if hepatic metastases are present - Negative HIV HCV and HBV status - Adequate bone marrow reserve: Platelet count>100X109 cells/L or platelet count <75X109 cells/L if bone marrow disease involvement, absolute neutrophile count (ANC)> 1,5 X109, hemoglobin>8 g/dl. - Able to adhere to the study visit schedule and other protocol requirements - Cardiac ejection fraction (MUGA scan or echocardiography) > 45% - Life expectancy > 6 months - Females of childbearing potential (FCBP) must have a negative serum or urine ß-hCG pregnancy test result within 7 days prior to the first dose of study drug. Females of non-childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy - Both females of childbearing potential and males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days after the last dose of study drug. - Measurable disease of at least 2 cm as detected by CT scan, assessed by site radiologist - Patients or they legally authorized representative must provide written informed consent Exclusion Criteria: - Any serious active disease or co-morbid medical condition (according to investigator's decision) - Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for = 3 years - Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form - Patients with congenital long QT syndrome, history of significant cardiovascular disease and/or taking drugs leading to significant QT prolongation - Corrected QT interval > 480 msec (using the Fridericia formula) - Low K+ (<3.8 mmol/L) and low Mg+ (<0.85 mmol/L) levels, except if corrected before beginning the chemotherapy - Pregnant or lactating females or men or women of childbearing potential not willing to use an adequate method of birth control for the duration of the study - Previous exposure to romidepsin or gemcitabine - CNS disease (meningeal and/or brain involvement by lymphoma) or testicular involvement - History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances - Active opportunistic infection |
Country | Name | City | State |
---|---|---|---|
Italy | A.O. SS. Antonio e Biagio e C. Arrigo | Alessandria | |
Italy | Istituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola | Bologna | |
Italy | Fondazione IRCCS Istituto Nazionale dei Tumori | Milano | |
Italy | A.O. Universitaria Citta' Della Salute E Della Scienza Di Torino | Torino |
Lead Sponsor | Collaborator |
---|---|
Fondazione Italiana Linfomi ONLUS |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Complete Remission (CR) Rate | Complete Remission is disappearance of all target lesions per the Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007)" | 18 months | |
Secondary | Percentage of Participants With Progression-Free Survival | The time from start of study treatment to first documentation of objective tumor progression or to death due to any cause, whichever comes first. PFS (progression-free survival) data will be censored on the day following the date of the last radiological assessment of measured lesions documenting absence of progressive disease for patients who do not have objective tumor progression and are still on study at the time of an analysis, are given antitumor treatment other than the study treatment or stem cell transplant, or are removed from study prior to documentation of objective tumor progression. Patients lacking an evaluation of tumor response after their first dose will have their event time censored at 1 day. Percentage of participants is an estimate based on Kaplan-Meier method. | 24 months | |
Secondary | Overall Survival is Measured From the Date of Study Entry to the Date of Patient's Death | OS (overall survival) is measured from the date of study entry to the date of patient's death. If the patient is alive or his vital status is unknown, the date of death will be censored at the date that the patient is last known to be alive. | 24 months | |
Secondary | Safety - Frequency of Toxicities Grade 3 and 4 | Frequency of toxicities was reported by type and grade according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). | 24 months | |
Secondary | Overall Response Rate (ORR) | ORR the proportion of patients who achieve CR (complete response), CRu (complete remission unconfirmed) or PR (partial response) relative to the per-protocol population. Disease response and progression will be evaluated according to the "Revised Response Criteria" for malignant lymphoma (Cheson et al. 2007). | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00038025 -
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
|
Phase 2 | |
Recruiting |
NCT02445404 -
Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL
|
Phase 2 | |
Completed |
NCT02168140 -
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
|
Phase 1 | |
Completed |
NCT01689220 -
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
|
Phase 1 | |
Terminated |
NCT01644253 -
Phase 1b Safety and Efficacy Study of TRU-016
|
Phase 1 | |
Completed |
NCT01435863 -
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
|
Phase 1 | |
Completed |
NCT01427881 -
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
|
Phase 2 | |
Terminated |
NCT00441025 -
The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL
|
Phase 2 | |
Completed |
NCT00078858 -
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
|
Phase 1/Phase 2 | |
Completed |
NCT00003196 -
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma
|
N/A | |
Active, not recruiting |
NCT04312841 -
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
|
Phase 2 | |
Recruiting |
NCT04040491 -
PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma
|
Phase 4 | |
Terminated |
NCT01678443 -
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
|
Phase 1 | |
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT02142530 -
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL
|
Phase 1 | |
Completed |
NCT02264613 -
ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
|
Phase 1/Phase 2 | |
Terminated |
NCT01408043 -
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
|
N/A | |
Completed |
NCT00131937 -
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
|
Phase 2 | |
Completed |
NCT00791947 -
A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT
|
Phase 2 | |
Recruiting |
NCT04880746 -
Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study
|
Phase 3 |